← Leaderboards
Jianxin Bao
Washington University
$7,612,755
Attributed
$7,612,755
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2008–21$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,612,755 · 10
By mechanism
R44$2,179,958 · 1
R01$2,084,251 · 2
R33$1,729,082 · 1
R41$1,203,856 · 5
R21$415,608 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Kerry Kornfeld$13,611,393
- Jay F Piccirillo$20,089,586
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventBaseFuturePharmaceutical PreparationsNoise-Induced Hearing LossMolecularDosePathway InteractionsAffectPresbycusisDosageNoiseMouse ModelSignal PathwayT-Type Calcium ChannelsHearing ImpairmentAntioxidantsResearch StudyUnited States Food And Drug AdministrationCochlear StructureAuditoryFree RadicalsCellular TargetingDrug Combinations
Grant awards (22)
Targeting multiple signaling pathways for tinnitus prevention and treatment$1,207,345
R44 · FY2021 · DC · contact PI
Targeting multiple signaling pathways for tinnitus prevention and treatment$972,613
R44 · FY2020 · DC · contact PI
Developing a Nutraceutical Product against Ototoxicity$205,183
R41 · FY2019 · DC · contact PI
An unique patient population for clinical trials against noise-induced hearing loss$99,872
R41 · FY2019 · DC · contact PI
An unique patient population for clinical trials against noise-induced hearing loss$224,700
R41 · FY2018 · DC · contact PI
Develop a new cisplatin-based drug combination with reduced ototoxicity$224,700
R41 · FY2017 · DC · contact PI
Developing a Nutraceutical Product against Noise-Induce Hearing Loss$224,700
R41 · FY2017 · DC · contact PI
AMELIORATION OF PRESBYCUSIS BY BLOCKING T-TYPE CALCIUM CHANNELS WITH ANTIEPILEPT$322,150
R01 · FY2016 · DC · contact PI
Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss$224,701
R41 · FY2016 · AT · contact PI
AMELIORATION OF PRESBYCUSIS BY BLOCKING T-TYPE CALCIUM CHANNELS WITH ANTIEPILEPT$318,928
R01 · FY2015 · DC · contact PI
AMELIORATION OF PRESBYCUSIS BY BLOCKING T-TYPE CALCIUM CHANNELS WITH ANTIEPILEPT$322,150
R01 · FY2014 · DC · contact PI
DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS$380,062
R33 · FY2013 · DC · contact PI
AMELIORATION OF PRESBYCUSIS BY BLOCKING T-TYPE CALCIUM CHANNELS WITH ANTIEPILEPT$201,552
R01 · FY2013 · DC · contact PI
DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS$163,319
R33 · FY2013 · DC · contact PI
AMELIORATION OF PRESBYCUSIS BY BLOCKING T-TYPE CALCIUM CHANNELS WITH ANTIEPILEPT$105,021
R01 · FY2013 · DC · contact PI
DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS$585,299
R33 · FY2012 · DC · contact PI
AMELIORATION OF PRESBYCUSIS BY BLOCKING T-TYPE CALCIUM CHANNELS WITH ANTIEPILEPT$323,000
R01 · FY2012 · DC · contact PI
DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS$600,402
R33 · FY2011 · DC · contact PI
DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS$187,608
R21 · FY2010 · DC · contact PI
DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS$228,000
R21 · FY2009 · DC · contact PI
Roles of Neuregulin-1 in Age Related Neuronal Changes$200,000
R01 · FY2009 · AG · contact PI
Roles of Neuregulin-1 in Age Related Neuronal Changes$291,450
R01 · FY2008 · AG · contact PI